23andMe Holding Co. is a leading genetic health and biopharmaceutical company. Lung Cancer Research Foundation (LCRF) in collaboration with 23andMe Holding Co, and 20 lung cancer advocacy organizations have announced a new study to help advance research in lung cancer.
The target of the Lung Cancer Genetics Study is to better understand the genetics of lung cancer patients. This will in turn work to improve detection and reduce lung cancer risk. Although lung cancer remains the top cause of cancer deaths among both men and women in the United States, yet there remains unknown about the disease and its causes.
Learning about the link between genetics and lung cancer can work to understand the risk and treatment. The aim is to understand more how genetics influence lung cancer. This would in turn work to improve its early detection and finding a cure.
“It is powerful to see the entire lung cancer community unite behind the Lung Cancer Genetics Study,” says Aubrey Rhodes, LCRF executive director. “Understanding genetic factors associated with lung cancer, and enabling researchers worldwide to securely access the data, will go a long way to improving early detection and treatment outcomes. LCRF is proud to be a part of what will certainly be an important initiative for lung cancer research.”
Lung cancer took more lives in the United States in 2020 alone as compared to breast, colorectal and prostate cancers combined. It is being estimated that in 2024, 234000 new cases will be diagnosed with lung cancer in the United States. Through this collaboration, LCRF and other advocate organizations, hope to help advance research towards finding a cure for this deadly disease.
The data from this study will be made available to approved researchers and access to scientific database will be available to non profit researchers and organizations at no cost.
The information shared in this blog is for educational purposes only. You should always consult with your healthcare provider for any medical needs.
Subscribe to our newsletter or follow us on Facebook or Twitter today to stay informed and never miss an update!